Hucog HP is a highly purified human chorionic gonadotropin (hCG) formulation designed for medical use in fertility treatment and hormonal regulation. Produced using recombinant DNA technology, it ensures exceptional batch-to-batch consistency and biological activity. This medication is prescribed under medical supervision to stimulate ovulation in women or testosterone production in men, supporting critical reproductive and endocrine functions with reliable pharmacokinetics.

Features

• Contains highly purified recombinant human chorionic gonadotropin (hCG)
• Standardized potency of 2000 IU, 5000 IU, and 10,000 IU per vial
• Lyophilized powder form for enhanced stability and reconstitution flexibility
• Includes bacteriostatic water for injection as diluent
• Manufactured under strict GMP (Good Manufacturing Practice) conditions
• Low impurity profile with high specific activity

Benefits

• Promotes final follicular maturation and triggers ovulation in women undergoing fertility treatment
• Supports luteinizing hormone (LH) surge simulation for timed ovulation induction
• Stimulates testosterone production in Leydig cells for treatment of hypogonadism in males
• Aids in corpus luteum maintenance during the luteal phase
• Used in combination protocols with other gonadotropins for controlled ovarian stimulation
• Provides predictable pharmacokinetics for precise treatment scheduling

Common use

Hucog HP is primarily used in assisted reproductive technology (ART), including in vitro fertilization (IVF) and intrauterine insemination (IUI) cycles. It is indicated for ovulation induction in anovulatory or oligo-ovulatory women who have undergone preliminary follicular maturation with follicle-stimulating hormone (FSH). In males, it is prescribed for prepubertal cryptorchidism not due to anatomical obstruction and for hypogonadotropic hypogonadism. Off-label uses may include weight loss protocols, though this application remains controversial and is not FDA-approved.

Dosage and direction

Dosage must be individualized based on patient response, indication, and treatment protocol. For ovulation induction: typically 5,000–10,000 IU administered as a single intramuscular injection when follicular maturation is achieved (as confirmed by ultrasound and estradiol levels). For male hypogonadism: 1,000–4,000 IU administered 2–3 times weekly via intramuscular injection. Reconstitute with provided diluent according to vial strength—gently swirl until clear solution forms. Do not shake vigorously. Administer immediately after reconstitution. Rotate injection sites to prevent lipoatrophy.

Precautions

Use under strict medical supervision with appropriate monitoring. In women: monitor for ovarian hyperstimulation syndrome (OHSS), which may manifest with abdominal pain, distension, nausea, vomiting, and weight gain. Multiple pregnancy risk increases with gonadotropin therapy. In men: monitor for precocious puberty in pediatric patients or fluid retention in those with cardiac, renal, or epileptic conditions. Androgen-responsive tumors may be stimulated. Use with caution in patients with asthma, epilepsy, migraine, or renal/cardiac impairment. Not recommended for patients with hormone-dependent malignancies.

Contraindications

Hypersensitivity to hCG or any component of the formulation. Primary ovarian failure (high FSH levels indicating non-responsive ovaries). Uncontrolled thyroid or adrenal dysfunction. Organic intracranial lesions (e.g., pituitary tumors). Abnormal uterine bleeding of undetermined etiology. Ovarian cysts or enlargement not due to polycystic ovary syndrome. Prostate cancer or other androgen-dependent neoplasms. Pregnancy (Category X)—contraindicated due to potential teratogenic risk.

Possible side effect

• Injection site reactions: pain, redness, swelling, or bruising
• Ovarian hyperstimulation syndrome (OHSS) with abdominal distension/pain
• Headache, irritability, restlessness, fatigue
• Gynecomastia in male patients
• Edema due to androgenic effects
• Mild fever, allergic reactions (rash, urticaria)
• Multiple gestation pregnancy
• Thrombboembolic events (rare but serious)

Drug interaction

May potentiate effects of other gonadotropins when used in combination protocols. Corticosteroids may enhance fluid retention risk. Androgens or anabolic steroids may exacerbate androgenic side effects. Drugs affecting pituitary-gonadal axis (e.g., GnRH analogs, oral contraceptives) may interfere with therapeutic response. No well-documented pharmacokinetic interactions, but caution advised with polypharmacy.

Missed dose

If a dose is missed, contact the prescribing physician immediately. Do not double the next dose to compensate. Timing is critical in ovulation induction protocols—missed doses may disrupt treatment cycle synchronization. For weekly regimens in males, administer as soon as remembered if within 48 hours of scheduled time; otherwise, wait until next scheduled dose.

Overdose

Overdose may precipitate severe OHSS in women, characterized by rapid weight gain, severe abdominal pain, vomiting, oliguria, and respiratory distress. In males, excessive doses may cause exaggerated androgenic effects including acne, hirsutism, and aggressive behavior. Treatment is supportive and symptomatic: hospitalization may be required for severe OHSS with fluid/electrolyte management, paracentesis, or thromboprophylaxis. No specific antidote exists.

Storage

Store unopened vials at 2–8°C (36–46°F); do not freeze. Protect from light. After reconstitution, use immediately—discard any unused portion. Do not use if solution appears cloudy or contains particulate matter. Keep out of reach of children. Avoid extreme temperature fluctuations.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Hucog HP is a prescription medication requiring thorough diagnostic evaluation and monitoring by a qualified healthcare provider. Individual results may vary. Not all uses described may be approved in your country—always follow local regulatory guidelines and prescribing information.

Reviews

Clinical studies demonstrate ovulation rates of approximately 80–90% in appropriately selected women when used with FSH priming. Meta-analyses of ART cycles show superior ovulation triggering compared to urinary hCG with reduced immunogenicity. Male hypogonadism studies indicate sustained testosterone production with long-term use. Patient reports frequently note satisfaction with treatment efficacy when properly monitored, though side effect profiles require careful management. Consistent batch potency and reliability are frequently cited advantages over non-recombinant formulations.